<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Gupta S</submitter><funding>BLRD VA</funding><funding>NEI NIH HHS</funding><pagination>38</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12859705</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>15(1)</volume><pubmed_abstract>&lt;h4>Purpose&lt;/h4>The inhibitor of differentiation 3 gene therapy via adeno-associated virus 5 (AAV5-Id3) effectively abrogated corneal fibrosis in vivo. This study examined the long-term tolerability and safety of AAV5-Id3 gene therapy for eyes in vivo using a rabbit model.&lt;h4>Methods&lt;/h4>Eighteen New Zealand White rabbits, segregated into three groups (naive, AAV5-naked, and AAV5-Id3; n = 6/group), were used. The clinical eye examinations with slit-lamp and multimodal corneal imaging were performed in live rabbits periodically to record the status of ocular and corneal health for up to 7 months. Thereafter, humane euthanasia was performed, and cellular and molecular changes in corneas were studied employing histopathologic, immunofluorescence, and quantitative reverse transcription polymer</pubmed_abstract><journal>Translational vision science &amp; technology</journal><pubmed_title>Long-Term Tolerability and Safety of AAV5-Id3 Gene Therapy to Eyes.</pubmed_title><pmcid>PMC12859705</pmcid><funding_grant_id>U01 EY031650</funding_grant_id><funding_grant_id>R01 EY030774</funding_grant_id><funding_grant_id>IK6 BX005646</funding_grant_id><funding_grant_id>I01 BX000357</funding_grant_id><pubmed_authors>Hesemann NP</pubmed_authors><pubmed_authors>Mohan RR</pubmed_authors><pubmed_authors>Gupta S</pubmed_authors><pubmed_authors>Hofmann AC</pubmed_authors><pubmed_authors>Sinha NR</pubmed_authors><pubmed_authors>Fraunfelder FW</pubmed_authors><pubmed_authors>Sinha PR</pubmed_authors><pubmed_authors>Martin LM</pubmed_authors><pubmed_authors>Kumar R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Long-Term Tolerability and Safety of AAV5-Id3 Gene Therapy to Eyes.</name><description>&lt;h4>Purpose&lt;/h4>The inhibitor of differentiation 3 gene therapy via adeno-associated virus 5 (AAV5-Id3) effectively abrogated corneal fibrosis in vivo. This study examined the long-term tolerability and safety of AAV5-Id3 gene therapy for eyes in vivo using a rabbit model.&lt;h4>Methods&lt;/h4>Eighteen New Zealand White rabbits, segregated into three groups (naive, AAV5-naked, and AAV5-Id3; n = 6/group), were used. The clinical eye examinations with slit-lamp and multimodal corneal imaging were performed in live rabbits periodically to record the status of ocular and corneal health for up to 7 months. Thereafter, humane euthanasia was performed, and cellular and molecular changes in corneas were studied employing histopathologic, immunofluorescence, and quantitative reverse transcription polymer</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Jan</publication><modification>2026-06-16T07:22:28.433Z</modification><creation>2026-06-16T03:09:53.788Z</creation></dates><accession>S-EPMC12859705</accession><cross_references><pubmed>41603714</pubmed><doi>10.1167/tvst.15.1.38</doi></cross_references></HashMap>